PressJanuary 18, 2023 Core One Labs’ Acquires GMP Drug Inc.: Positioning Itself as a Full Cycle Psychedelics Supply Chain Solution for Clinicians, Researchers and Other Drug Developers
PressJanuary 18, 2023 FSD Pharma submits its phase-1 Clinical Trial Application for Lucid-MS (Lucid-21-302) for first-in-human safety and tolerability investigation
PressJanuary 18, 2023 Optimi Health Expands Functional Mushroom Sales Network With Additional Brokers, Distribution Agreements
PressJanuary 18, 2023 Israel-Based Clearmind Announces Additional Positive Results from the Third Part of its Pre-Clinical Study for Cocaine Addiction Treatment
PressJanuary 16, 2023 Mindbloom partners with This is Jane Project to offer affordable at-home ketamine therapy to trauma survivors
PressJanuary 16, 2023 atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
PressJanuary 12, 2023 Jaguar Health and Filament Health, with Funding from One Small Planet, Form Joint Venture Magdalena Biosciences to Develop Botanical Pharmaceutical Drug Candidates for Mental Health Illnesses
PressJanuary 12, 2023 Cybin Inc. Selects Generalized Anxiety Disorder as Target Indication for CYB004
PressJanuary 10, 2023 Irwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical Companies in the US
PressJanuary 10, 2023 Israel-Based Clearmind Medicine Successfully Completes Production of CMND-100 Drug Candidate for Clinical Trial
PressJanuary 10, 2023 Silo Pharma Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation
BlogJanuary 10, 2023 Chad Harman, CEO of Psycheceutical, Sits in the Investor Hotseat on January 12th
PressJanuary 9, 2023 Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104
